Hypotensive Agents Reduce Bleeding in ESS
Diltiazem, esmolol, dexmedetomidine, labetalol, and clonidine were associated with improved surgical field quality and comparable safety profiles
-
By
-
Olivia Anderson
-
January 30, 2026
-
Clinical Scorecard: Hypotensive Agents Reduce Bleeding in ESS
At a Glance
| Category | Detail |
|---|
| Condition | Endoscopic Sinus Surgery (ESS) |
| Key Mechanisms | Controlled hypotension to reduce intraoperative bleeding |
| Target Population | Patients undergoing endoscopic sinus surgery for chronic inflammatory sinonasal conditions |
| Care Setting | Intraoperative surgical setting |
Key Highlights
- Diltiazem showed the greatest reduction in bleeding scores.
- Dexmedetomidine significantly lowered mean arterial pressure by approximately 30 mm Hg.
- Esmolol and labetalol associated with shorter emergence times.
- Safety profiles were comparable across all agents studied.
- Variability in dosing and outcome definitions may limit generalizability.
Guideline-Based Recommendations
Diagnosis
- Assess chronic rhinosinusitis and nasal polyposis indications for ESS.
Management
- Select hypotensive agents based on bleeding control, hemodynamic stability, and recovery time.
Monitoring & Follow-up
- Monitor intraoperative bleeding scores and hemodynamic parameters.
Risks
- Consider variability in subjective measures of bleeding and visualization.
Patient & Prescribing Data
Patients undergoing ESS with chronic sinonasal conditions.
Agent selection should be tailored to individual patient characteristics and procedural goals.
Clinical Best Practices
- Utilize multiple pharmacologic options for controlled hypotension during ESS.
- Standardize timing and dosing protocols in future studies.
- Emphasize individualized treatment strategies.
References
